FDA Approves DESOXIMETASONE — Saptalis Pharmaceuticals, LLC.

# FDA Approves Saptalis Pharmaceuticals' Generic Desoximetasone Topical Treatment Saptalis Pharmaceuticals, LLC received FDA approval for its generic desoximetasone topical formulation on January 6, 2017, expanding the competitive landscape in the topical corticosteroid market and potentially pressuring pricing for branded alternatives. The approval of this widely-used dermatological treatment is expected to increase patient access to cost-effective therapy for inflammatory skin conditions.